Printer Friendly

PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES FORMATION OF PROCESS DIVISION

PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES FORMATION OF PROCESS DIVISION
 CAMBRIDGE, Mass., July 20 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today the formation of its Process Division, The division will provide resources dedicated to the application of the company's patented POROS(R) chromatography media to process- and manufacturing-scale purification of biopharmaceuticals. Noubar B. Afeyan, Ph.D., president and chief executive officer of the company, stated, "The functional managers of this division combine more than 40 years of experience in the development, marketing and technical support of large-scale purification processes." The formation of this Process Division follows the company's recent filing of a Drug Master File relating to its production processes with the U.S. Food and Drug Administration.
 The company named Daniel K. Freymeyer II vice president-process to head up the new division. Freymeyer was previously vice president- sales of the company. Prior to joining PerSeptive, he was regional sales manager at Sepracor Inc. and held various sales positions for the previous nine years at the Process Division of Pharmacia Bio-Systems, Inc. The company's Process Division will be comprised of process sales specialists, process engineers and applications chemists both in the United States and overseas. The division's scientists and engineers will focus their efforts on the application of the company's materials to the unique purification process needs of its customers. Most of this work will be performed at the company's principal laboratories in Cambridge. Applications laboratories will also be established in Germany and Japan this fall.
 Dr. Afeyan continued, "The creation of this division represents a substantial commitment by PerSeptive to the large-scale manufacture of biopharmaceuticals. Many companies have made a commitment to selling analytical tools to this industry, but few have dedicated substantial resources to a large-scale purification."
 The Process Division's charter is to supply tools that significantly increase productivity in the manufacture of biopharmaceuticals. Biopharmaceutical developers have used the company's patented Perfusion Chromatography(R) process to achieve separations of proteins, peptides and oligonucleotides in any chromatography mode at throughputs 10 to 1,000 times greater than conventional liquid chromatography. These results have been achieved without loss in resolution or binding capacity. The Process Division will offer the biopharmaceutical industry chromatography media and process technologies that will greatly increase flow rates, improve recoveries and significantly reduce column volumes. These performance advantages in turn translate into higher plant throughput, more flexible manufacturing processes and reduced plant size.
 Robert B. Anacone, senior vice president-marketing and sales, stated, "The formation of the Process Division is another step in the progress we have made in introducing our novel purification tools to the market. Our ultimate goal is to enable biopharmaceutical companies to achieve the same kinds of manufacturing efficiencies typical in other kinds of chemical production processes, such as the manufacture of conventional pharmaceuticals. We believe that these kinds of efficiencies are critical for the industry to reap the potential unleashed by scientific developments in cell biology, biochemistry and genetic engineering."
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 Perfusion Chromatography and POROS are registered trademarks and ImmunoDetection and Rational Surface Design are trademarks of the company.
 -0- 7/20/92
 /CONTACT: Robert Fein, vice president and CFO, or Robert B. Anacone, senior vice president-marketing and sales, 617-621-1787/
 (PBIO) CO: PerSeptive Biosystems ST: Massachusetts IN: MTC SU:


TM -- NE005 -- 0605 07/20/92 09:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:611
Previous Article:CENGIZ S. KURKCU NAMED DIRECTOR - FINANCE AT THE TIMKEN COMPANY
Next Article:CHARTER ONE FINANCIAL, INC. REPORTS RECORD OPERATING RESULTS FOR THE 1992 SECOND QUARTER
Topics:


Related Articles
ROBERT B. ANACONE NAMED SENIOR VICE PRESIDENT, MARKETING AND SALES AT PERSEPTIVE BIOSYSTEMS
PERSEPTIVE BIOSYSTEMS NAMES JOHN CURLING VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT
PERSEPTIVE BIOSYSTEMS ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS, INC.'S PROCESS DIVISION ANNOUNCES PILOT-SCALE SYSTEM MANUFACTURING AGREEMENT
PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS SIGN FINAL AGREEMENT TO FORM PERISIS
PERSEPTIVE BIOSYSTEMS NAMES ALAIN MASSOT SENIOR VICE PRESIDENT, INTERNATIONAL
PerSeptive Biosystems to Own 1.6 Million Shares of Millennium Pharmaceuticals Following Chemgenics Pharmaceuticals' Merger with Millennium
PerSeptive Biosystems Appoints Heiko Wurth as Managing Director of PerSeptive Biosystems GmbH and European Distributors
AMERSHAM PHARMACIA BIOTECH WINS IMPORTANT PATENT INFRINGEMENT DISPUTE AGAINST PERSEPTIVE.
Amersham Pharmacia Biotech Wins Important Patent Infringement Dispute Against PerSeptive.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters